Home>Latest

Pudong biomedicine steps up global reach

english.pudong.gov.cn Updated:2026-06-05

Pudong New Area is accelerating its biomedicine push through ties among industry, universities, hospitals and research institutes, with recent moves spanning a Brazil-praised surgical robot, nearly 400 million yuan ($59.04 million) in financing and a diagnostics education project at Shanghai Jiao Tong University (SJTU).

Brazilian President Luiz Inácio Lula da Silva tested MicroPort MedBot's Toumai surgical robot in a remote surgery simulation at Hospital de Amor and praised the innovation for expanding access and strengthening Brazil's public health system.

 图片6.png

Brazilian President Luiz Inácio Lula da Silva tests the MEDBOT surgical robot. [Photo/WeChat ID: pdnews]

The system is moving toward public-sector use in Brazil, with initial procedures in the Unified Health System planned for July, following a 2024 Latin American animal experiment and regulatory approvals in both China and Brazil.

Meanwhile, Bivision, a Shanghai-based company focused on imaging-guided targeted radionuclide therapy, said its nearly 400 million yuan Series B round will fund confirmatory trials, platform upgrades and the building of a radiopharmaceutical R&D center.

Its lead pipeline is being developed for clinical translation, while another multi-tumor candidate has entered Phase I/II studies, reinforcing Pudong's efforts to turn laboratory breakthroughs into therapies with global potential and wider clinical impact.

At SJTU School of Medicine, Siemens Healthineers Diagnostics launched an education grant program to support frontier IVD research, academic forums and scholarships, further deepening long-term industry-academia collaboration, talent training and clinical translation.